Ingredient comparison

Semaglutide vs Tirzepatide

Last updated

In SURMOUNT-5, a head-to-head trial of the injections, mean weight change was −13.7% on semaglutide (Wegovy) and −20.2% on tirzepatide (Zepbound) over 72 weeks. Prices and approved uses vary by brand and dose.

Semaglutide vs Tirzepatide: lowest prices now

  • Semaglutide: lowest FDA-approved

    NovoCare (Novo Nordisk)

    $149/30 days · about $149 per 30 days

  • Semaglutide: lowest compounded on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Tirzepatide: lowest FDA-approved

    LillyDirect (Eli Lilly)

    $299-$449/28 days · about $320 per 30 days

  • Tirzepatide: lowest compounded on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

Every cash quote was checked on or after .Data feeds · Nov 16, 2026 UTC
Semaglutide vs Tirzepatide: overview
CompareSemaglutideTirzepatide
What it is for

FDA-approved for

  • Weight loss
  • Type 2 diabetes
  • Heart risk
  • Kidney
  • Liver

FDA-approved for

  • Weight loss
  • Type 2 diabetes
  • Heart risk
  • Sleep apnea
Brands
Route & frequency

Subcutaneous injection (Ozempic, Wegovy); oral tablet (Rybelsus, oral Ozempic, Wegovy pill)

Once weekly (injectable); once daily (oral)

Subcutaneous injection

Once weekly

FDA shortage report

National reporting does not confirm stock at your pharmacy.

Coverage & source records

National reporting does not confirm stock at your pharmacy.

Coverage & source records
What was tested together

Direct comparative evidence

SURMOUNT-5 (nejm.org)

Peer-reviewed paper

Wegovy injection vs Zepbound

Adults with obesity, or overweight with a weight-related condition, without diabetes.

751 participants · 72 weeks (nejm.org/doi/full/10.1056/NEJMoa2416394) · Randomized, open-label

Mean weight change (% of body weight)

Treatment-regimen analysis, regardless of treatment adherence.

SURMOUNT-5: Mean weight change at 72 weeks. Treatment-regimen analysis, regardless of treatment adherence.
Treatment & doseChange
Semaglutide (Wegovy)1.7 or 2.4 mg weekly injection−13.7% (nejm.org)
Tirzepatide (Zepbound)10 or 15 mg weekly injection−20.2% (nejm.org)

Tirzepatide produced greater mean weight reduction in this trial. Both groups used their maximum tolerated dose.

This trial did not test Wegovy tablets or Wegovy HD. It was not powered to establish a safety or tolerability advantage. Study averages do not predict an individual's result.

Read the paper (nejm.org)PubMed abstract (pubmed.ncbi.nlm.nih.gov)Sponsor's analysis details (investor.lilly.com)Reviewed

SURPASS-2 (nejm.org)

Peer-reviewed paper

Ozempic injection vs Mounjaro

Adults with type 2 diabetes inadequately controlled with metformin.

1,879 participants · 40 weeks (nejm.org/doi/full/10.1056/NEJMoa2107519) · Randomized, open-label

Mean HbA1c change (percentage points)

Treatment-regimen analysis, regardless of treatment adherence or rescue therapy.

SURPASS-2: Mean HbA1c change at 40 weeks. Treatment-regimen analysis, regardless of treatment adherence or rescue therapy.
Treatment & doseChange
Semaglutide (Ozempic)1 mg weekly injection−1.86 pp (nejm.org)
Tirzepatide (Mounjaro)5 mg weekly injection−2.01 pp (nejm.org)
Tirzepatide (Mounjaro)10 mg weekly injection−2.24 pp (nejm.org)
Tirzepatide (Mounjaro)15 mg weekly injection−2.3 pp (nejm.org)

Each tirzepatide dose lowered HbA1c more than semaglutide 1 mg in this trial.

This trial did not compare Ozempic 2 mg or tablets. HbA1c changes are percentage points, not relative percentages or weight-loss results. Study averages do not predict an individual's result.

Read the paper (nejm.org)PubMed abstract (pubmed.ncbi.nlm.nih.gov)Sponsor's analysis details (investor.lilly.com)Reviewed
Product-specific self-pay

What the quoted price covers

Lowest tracked quotes for FDA-approved products, selected separately for each price basis. Entry prices may refer to different brands or formulations. Supply periods, eligibility, refill deadlines, and additional fees can change what you pay.

Semaglutide vs Tirzepatide: sourced cash quotes
CompareSemaglutideTirzepatide
Advertised entry price
$149/30 days (pharmacy.amazon.com/Novo-Nordisk-Inc-WEGOVY-1-5-MG-TABLET-Bottle-30-Tablet/dp/B0GD6568YL)

Wegovy pill via Amazon Pharmacy

Amazon Pharmacy

without insurance, 1.5 mg; includes the manufacturer coupon if eligible (list price $1,348.80); prescription required

30-day supply (pharmacy.amazon.com)

$149 per 30 days at this quoted rate

Checked on pharmacy.amazon.com

Price conditions

without insurance, 1.5 mg; includes the manufacturer coupon if eligible (list price $1,348.80); prescription required

Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

30-day supply

$299/28 days (pharmacy.amazon.com/ZEPBOUND-KWIKPEN-2-5-MG-DOSE-PEN-INJ/dp/B0GP27N9T3)

Zepbound KwikPen via Amazon Pharmacy

Amazon Pharmacy

without insurance, 2.5 mg; includes the manufacturer coupon if eligible (list price $498.98); prescription required

28-day supply (pharmacy.amazon.com)

≈ $320.36 per 30 days at this quoted rate

Offer through

Checked on pharmacy.amazon.com

Price conditions

without insurance, 2.5 mg; includes the manufacturer coupon if eligible (list price $498.98); prescription required

The 7.5 mg KwikPen is also $449. Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

28-day supply

At the named trial dose
$349/28 days (pharmacy.amazon.com/Novo-Nordisk-WEGOVY-2-4-MG-0-75-ML-PEN-INJECTOR-Box-3-Milliliter/dp/B09BHXXL2R)

Wegovy pen via Amazon Pharmacy

At 2.4 mg

Amazon Pharmacy

without insurance, 2.4 mg; includes the manufacturer coupon if eligible (list price $1,349.01)

28-day supply (pharmacy.amazon.com)

≈ $373.93 per 30 days at this quoted rate

Checked on pharmacy.amazon.com

Price conditions

without insurance, 2.4 mg; includes the manufacturer coupon if eligible (list price $1,349.01)

Amazon fills a prescription you already have and delivers in all 50 states. Its $199 for 0.25 mg "Includes $100.00 off with manufacturer coupon if eligible": Novo Nordisk's coupon, which its terms limit to a new patient's first two 28-day fills, filled by Dec 31, 2026. FDA-approved product.

28-day supply

$449/28 days (pharmacy.amazon.com/ZEPBOUND-KWIKPEN-15-MG-DOSE-PEN-INJ/dp/B0GP1V2X9V)

Zepbound KwikPen via Amazon Pharmacy

At 15 mg

Amazon Pharmacy

without insurance, with Lilly's self-pay card, which ends 12/31/2026 and requires each refill within 45 days of the previous delivery, as Lilly's Zepbound savings page states (otherwise Lilly's regular $699); 15 mg; includes the manufacturer coupon if eligible (list price $699)

28-day supply (pharmacy.amazon.com)

≈ $481.07 per 30 days at this quoted rate

Offer through

Checked on pharmacy.amazon.com

Price conditions

without insurance, with Lilly's self-pay card, which ends 12/31/2026 and requires each refill within 45 days of the previous delivery, as Lilly's Zepbound savings page states (otherwise Lilly's regular $699); 15 mg; includes the manufacturer coupon if eligible (list price $699)

The 7.5 mg KwikPen is also $449. Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

28-day supply

Every offerAll 952 offersAll 885 offers

USD self-pay, not insurance or pharmacy acquisition cost. A trial dose is not a personal dosing recommendation. Compounded offers are shown separately in the offer browser and are not FDA-approved.

Separate studies

Trial outcomes in context

Each result belongs to its own trial, population, dose, and analysis. Weight loss, HbA1c change, and adverse events may come from different studies even within one ingredient. These are study averages, not predictions of your result.

Semaglutide vs Tirzepatide: individual trial outcomes
CompareSemaglutideTirzepatide
Weight change
−14.9% (nejm.org/doi/full/10.1056/NEJMoa2032183) (-14.9% at 68 wks · STEP 1 · 2.4 mg weekly (Wegovy))

-14.9% at 68 wks

STEP 1 (nejm.org)

2.4 mg weekly (Wegovy)

Accounts for treatment discontinuation

Study context

The headline is the standard 2.4 mg maintenance dose (Wegovy), the dose used in STEP 1 and one of the permitted doses in SURMOUNT-5. Other doses and formulations have their own trials, including STEP UP and OASIS 4. Their results are not interchangeable.

−20.9% (nejm.org/doi/full/10.1056/NEJMoa2206038) (-20.9% at 72 wks · SURMOUNT-1 · 15 mg weekly (Zepbound))

-20.9% at 72 wks

SURMOUNT-1 (nejm.org)

15 mg weekly (Zepbound)

Accounts for treatment discontinuation

Study context

SURMOUNT-1 studied adults with obesity or overweight without diabetes. This result belongs to the 15 mg arm and the treatment-regimen analysis; other doses and analyses have different results.

HbA1c change (percentage points)
−1.6 pp (thelancet.com/journals/lancet/article/PIIS0140-6736(21)00213-0/abstract) (-1.6% at 68 wks · STEP 2 · HbA1c change in percentage points)

-1.6 percentage points at 68 wks

STEP 2 (thelancet.com)
−2.3 pp (investor.lilly.com/news-releases/news-release-details/lillys-surpass-2-results-published-new-england-journal-medicine) (-2.3% at 40 wks · SURPASS-2 · HbA1c change in percentage points)

-2.3 percentage points at 40 wks

SURPASS-2 (investor.lilly.com)
Adverse events

Stopped treatment for adverse events

7% (nejm.org/doi/full/10.1056/NEJMoa2032183) (7.0% vs 3.1% placebo · STEP 1 (2.4 mg, 68 wks, obesity))

Reported nausea

44.2% (nejm.org/doi/full/10.1056/NEJMoa2032183) (Nausea in the drug arm · STEP 1 (2.4 mg, 68 wks, obesity))

STEP 1 (2.4 mg, 68 wks, obesity)

Stopped treatment for adverse events

6.2% (nejm.org/doi/full/10.1056/NEJMoa2206038) (6.2% vs 2.6% placebo (15 mg) · SURMOUNT-1 (15 mg, 72 wks, obesity))

Reported nausea

31% (nejm.org/doi/full/10.1056/NEJMoa2206038) (Nausea in the drug arm · SURMOUNT-1 (15 mg, 72 wks, obesity))

SURMOUNT-1 (15 mg, 72 wks, obesity)

From FDA and CMS records

Timing, generics and coverage

Read from each FDA label, FDA's Orange Book and CMS's Part D files, and updated when they change.

BrandSoonest top doseHalf-lifeGeneric approved?Patent on the medicine toOn Medicare Part D, 2025
Ozempic2 mg from week 13about 1 weekNot yet: tentative onlyDec 5, 20312,044,798
Wegovy7.2 mg from week 21about 1 weekNoDec 5, 2031108,843
Rybelsus14 mg from day 61about one weekNoMay 2, 2034280,455
Mounjaro15 mg from week 21about 5 daysNoJun 14, 20391,592,517
Zepbound15 mg from week 21about 5-6 daysNoMay 13, 2036160,298

How long each takes · Generics and patents · Who covers what

Check the product label

Approved uses & full records

Semaglutide

Indications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.

806 registered ingredient studies (clinicaltrials.gov/search). Count checked . Research activity, not a measure of evidence quality.

Open full record

Tirzepatide

Indications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.

317 registered ingredient studies (clinicaltrials.gov/search). Count checked . Research activity, not a measure of evidence quality.

Open full record
Reading the comparison

Common questions

Is Semaglutide or Tirzepatide better for weight loss?

SURMOUNT-5 compared them directly: Tirzepatide produced greater mean weight reduction in this trial. Both groups used their maximum tolerated dose. This trial did not test Wegovy tablets or Wegovy HD. It was not powered to establish a safety or tolerability advantage. Side effects, price and what you can stay on also decide it, with your prescriber.

Is Semaglutide or Tirzepatide safer?

We know of no trial set up to answer that. Stopping because of side effects, each in its own trial and not a head-to-head figure: Semaglutide 7.0% vs 3.1% placebo (STEP 1 (2.4 mg, 68 wks, obesity)) (nejm.org); Tirzepatide 6.2% vs 2.6% placebo (15 mg) (SURMOUNT-1 (15 mg, 72 wks, obesity)) (nejm.org). Each FDA label lists its own warnings, and which ones matter depends on your health.

What Tirzepatide dose is equivalent to Semaglutide?

No FDA label sets a dose of Semaglutide that equals a dose of Tirzepatide, and we know of no trial that defines one. SURMOUNT-5 compared Semaglutide (Wegovy) at 1.7 or 2.4 mg weekly injection and Tirzepatide (Zepbound) at 10 or 15 mg weekly injection, which is a comparison of those doses, not a conversion between them. Switching is a prescriber's decision, and each label sets its own starting dose and steps.

Which costs less: Semaglutide or Tirzepatide?

Compare the named products and price conditions below. A tracked entry quote can be a different brand or formulation from the product studied in a trial. A trial-dose quote applies only to the named product and dose; neither figure is an estimate of your whole treatment cost or an insurance quote.

Do these trial results tell me which medication is best?

Direct trials compare the treatments, doses, and participants they studied. Results from separate trials differ in population, duration, dose, and analysis, so their percentages do not establish a treatment ranking. Discuss your medical history and the specific product label with a licensed clinician.

Does FDA shortage status mean my pharmacy has stock?

No. FDA shortage records describe national supply reports and covered presentations, not inventory at an individual pharmacy. Unknown status means the data cannot establish a current assessment. Confirm local stock with your pharmacy.

Updated automatically

What changed for Semaglutide and Tirzepatide

Written from each source's own record as it changes. Every change on GLPcompare

Automated feed checks do not constitute a clinical or editorial review. Sources & methodology

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.